McInnes B K
J Urol. 1980 Aug;124(2):171-4. doi: 10.1016/s0022-5347(17)55360-4.
Hematuria secondary to sickle cell hemoglobinopathy was first reported by Abel and Brown in 1948. They noted sickled erythrocytes in a kidney removed for suspected tumor. Since then there have been numerous reports attributing hematuria to the abnormal hemoglobins that produce sickling of red cells. Although presently a well established entity the management of this fairly unique form of hematuria is far from standardized. The pathogenesis of the condition is fairly well understood and several modalities of treatment have been tried--many of which have a sound physiological basis in their use but a randomized prospective study in a large series of patients has yet to be performed. Herein is reviewed the current concepts of the etiology, diagnosis and management of this unusual form of hematuria.
1948年，阿贝尔和布朗首次报告了镰状细胞血红蛋白病继发的血尿。他们在因疑似肿瘤而切除的肾脏中发现了镰状红细胞。从那时起，有许多报告将血尿归因于导致红细胞镰变的异常血红蛋白。尽管目前这是一个已被充分认识的病症，但这种相当独特的血尿形式的治疗远未标准化。该病症的发病机制已得到相当充分的理解，并且已经尝试了几种治疗方式——其中许多在使用时有合理的生理学基础，但尚未对大量患者进行随机前瞻性研究。本文回顾了这种不寻常的血尿形式的病因、诊断和治疗的当前概念。
